About

GV Correct is a US-based medical technology company developing the world's first non-invasive smart wearable and software platform for correcting lower-limb alignment deformities in children. Our flagship product, SmartAlign, addresses genu valgum (knock knees) and genu varum (bowed legs) — conditions that affect millions of children worldwide and, when left untreated, often progress to require highly invasive orthopedic intervention or surgery.
The standard of care for pediatric lower-limb alignment conditions has remained largely unchanged for decades: monitor, wait, and intervene later if natural correction does not occur. For families whose children fall into the category that does not self-correct, the options have been limited — rigid bracing, casting, or surgical procedures that carry significant recovery burden. GV Correct was founded on a different premise: that early, consistent, data-driven treatment during the pediatric growth window produces meaningfully better outcomes than watchful waiting.
Our technology is rooted in more than a decade of clinical research conducted at the University of Tartu, one of Europe's leading research universities, located in Estonia. The corrective garment system was developed and validated by a team of physiotherapy and biomechanics researchers, including co-inventors Arved Vain PhD, Anna-Liisa Tamm PhD, and Ivi Vaher PhD. The foundational research was published in peer-reviewed, indexed academic journals and forms the clinical evidence base on which GV Correct is built. The platform is patented in both the United States and the European Union.
The SmartAlign system combines three integrated components: a smart compression garment embedded with MEMS force sensors, a companion mobile application for Android and iOS, and physician and parental dashboards for remote monitoring and progress tracking. Together, these components turn passive garment wear into active, data-driven therapy. Sensors capture real-time pressure and alignment data during wear. That data is transmitted via Bluetooth to the companion app, where parents receive adherence feedback and progress updates. Physicians access a clinical dashboard that allows remote monitoring between appointments — replacing the black box of at-home treatment with continuous, actionable insight.
GV Correct is classified as an FDA Class I exempt device under 21 CFR 890.3475, a deliberate regulatory strategy that enables a faster path to US commercialization without requiring 510(k) premarket clearance. This classification reflects the non-invasive, non-implantable nature of the device and positions GV Correct for a commercial launch target of Q1 2027 following seed funding deployment and product validation.
The company's go-to-market strategy follows a phased model. Phase 1 focuses on direct-to-consumer distribution, reaching parents of children with diagnosed knock knees through digital acquisition and pediatric referral networks. This phase is designed to validate the commercial model, generate real-world adherence and outcome data, and build the clinical evidence base required for Phase 2. Phase 2 targets clinical and institutional partnerships with children's hospitals and pediatric orthopedic practices, building prescriber-driven demand and co-authored outcome studies. Phase 3, planned post-2027, pursues insurance reimbursement pathways and integrated delivery network contracts as clinical outcome data matures.
GV Correct is led by an experienced transatlantic team spanning medtech commercialization, regulatory strategy, product development, and business development, with scientific co-inventors from the University of Tartu engaged as ongoing advisors. The company is currently raising a $3 million Seed round to fund product development, regulatory preparation, clinical validation, and US market entry.
The pediatric orthopedic correction market represents a significant and underserved opportunity in medical device innovation. GV Correct is building the category-defining platform — starting with knock knees, expanding to bowlegs, and establishing the data infrastructure and clinical credibility to grow into the broader pediatric orthopedic alignment space. GV Correct. Align today, thrive tomorrow.